ASTS
AST SpaceMobile, Inc.
ASTS has the edge over DXC overall, supported by stronger fundamentals and stronger valuation.
DXC
DXC Technology Company
DXC has lower modeled downside risk, despite its lower overall score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
DXC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
DXC's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
DXC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 5.7x | $14.85 | — |
| Cheap | 6.9x | $4.77 | -68% |
| Fair | 12x | $8.59 | -42% |
| Current | 22x | $14.85 | — |
| Expensive | 47x | $32.15 | +117% |
Historical ranges are pointers, not guarantees.
DXC's PE is in its fair range at 22x. On analysts' estimates for next year's earnings, today's price would be 5.7x, in its cheap range.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
DXC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect DXC's earnings, revenue and profitability to hold roughly steady.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
DXC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.58 | +274% |
| Q3 2026 | $0.69 | -66% |
| Q2 2026 | $0.74 | -64% |
| Q1 2026 | $0.10 | -95% |
| Q4 2025 | $2.32 | +$2.65 |
| Q3 2025 | $2.02 | +1088% |
| Q2 2025 | $2.05 | +377% |
| Q1 2025 | $2.10 | +357% |
| Q4 2024 | -$0.33 | +$1.48 |
DXC has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over DXC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
DXC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3B | -4% |
| Q2 2026 | $3B | -5.1% |
| Q1 2026 | $3.1B | -1.2% |
| Q4 2025 | $3.2B | -1% |
| Q3 2025 | $3.2B | -2.5% |
| Q2 2025 | $3.2B | -2.4% |
| Q1 2025 | $3.2B | -6.4% |
| Q4 2024 | $3.2B | -5.1% |
DXC's revenue fell from its 2019 peak and has held roughly level since: $3B last quarter, down 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -1.9 points |
| Q2 2026 | 5% | -1.8 points |
| Q1 2026 | 7.6% | +0.3 points |
| Q4 2025 | 8.2% | -0.6 points |
| Q3 2025 | 8% | -0.6 points |
| Q2 2025 | 6.8% | 0 points |
| Q1 2025 | 7.3% | -1.1 points |
| Q4 2024 | 8.9% | +1.3 points |
DXC has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
DXC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $143M | -61% |
| Q2 2026 | $359M | +151% |
| Q1 2026 | $169M | -29% |
| Q4 2025 | $359M | -37% |
| Q3 2025 | $365M | +137% |
| Q2 2025 | $143M | -25% |
| Q1 2025 | $238M | -1.7% |
| Q4 2024 | $568M | -15% |
DXC has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DXC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 0.9x | Very low |
DXC's net debt is less than a year of its operating earnings (EBITDA).
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
DXC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 76.3 | Neutral |
DXC's weekly RSI is 65 (neutral) and its Stochastic is 76 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
DXC PE vs Technology Sector
| Metric | DXC | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 28x | 23% below |
| PE % | 63 | 35 | 28 pts above |
DXC is trading at 22x earnings, a 23% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
DXC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.6 | 9.4% above |
| 20 week MA | $11.8 | 26% above |
| 50 week MA | $12.1 | 22% above |
| 100 week MA | $14.0 | 6.1% above |
| 200 week MA | $18.1 | 18% below |
DXC has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
DXC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.7 | $22.9 | -38% |
| 2021 | $22.9 | $32.6 | +42% |
| 2022 | $32.6 | $26.5 | -19% |
| 2023 | $26.5 | $22.9 | -14% |
| 2024 | $22.9 | $20.2 | -12% |
| 2025 | $20.2 | $15.1 | -25% |
| 2026 YTD | $15.1 | $14.9 | -1.7% |
DXC has the edge over ASTS on returns for 2026, with the stronger performance.